UroGen Pharma Expects Full-year 2024 JELMYTO Revenue To Be Below The Low End Of Previously Provided Guidance Range
UroGen Pharma Expects Full-year 2024 JELMYTO Revenue To Be Below The Low End Of Previously Provided Guidance Range
UroGen Pharma預計2024賈爾米託全年營業收入將低於先前提供的指導區間的下限
The Company does expect JELMYTO to achieve low double-digit year-over-year revenue growth for the full year 2024.
公司預計JELMYTO在2024財年將實現低兩位數的年度營業收入增長。
With respect to the Company's previously provided full-year 2024 operating expenses guidance, the Company expects to be toward the midpoint of the guidance range, including non-cash share-based compensation expense of $9 to $13 million, subject to market conditions.
關於公司此前提供的2024財年全年營業費用指引，公司預計將位於指引區間的中點位置，包括非現金股份補償費用爲9至1300萬美元，視市場情況而定。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間